Lexicon Pharmaceuticals Enters Material Definitive Agreement
Ticker: LXRX · Form: 8-K · Filed: Mar 28, 2025
Sentiment: neutral
Topics: material-agreement, filing
Related Tickers: LXRX
TL;DR
Lexicon Pharma just signed a big deal, filing shows.
AI Summary
On March 27, 2025, Lexicon Pharmaceuticals, Inc. entered into a material definitive agreement. The filing also includes financial statements and exhibits related to this agreement. The company is headquartered in The Woodlands, Texas.
Why It Matters
This filing indicates a significant new contract or partnership for Lexicon Pharmaceuticals, which could impact its future financial performance and strategic direction.
Risk Assessment
Risk Level: medium — Entering into material definitive agreements can carry inherent risks related to the terms, obligations, and potential outcomes of the agreement.
Key Players & Entities
- Lexicon Pharmaceuticals, Inc. (company) — Registrant
- March 27, 2025 (date) — Date of earliest event reported
- The Woodlands, Texas (location) — Principal executive offices
FAQ
What type of material definitive agreement did Lexicon Pharmaceuticals enter into?
The filing states that Lexicon Pharmaceuticals, Inc. entered into a material definitive agreement on March 27, 2025, but the specific details of the agreement are not provided in this summary.
What is the primary business of Lexicon Pharmaceuticals, Inc.?
Lexicon Pharmaceuticals, Inc. is in the business of Pharmaceutical Preparations, as indicated by its Standard Industrial Classification code [2834].
When was this 8-K filing submitted?
This 8-K filing was submitted on March 28, 2025.
What is the address of Lexicon Pharmaceuticals' principal executive offices?
The principal executive offices of Lexicon Pharmaceuticals are located at 2445 Technology Forest Blvd., 11th Floor, The Woodlands, Texas 77381.
What is the SEC file number for Lexicon Pharmaceuticals?
The SEC file number for Lexicon Pharmaceuticals is 000-30111.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 28, 2025 regarding LEXICON PHARMACEUTICALS, INC. (LXRX).